Ewing sarcoma is a destructive sarcoma of the soft tissue and the
bones, which can occur at any age with the maximum rate of incidence
recorded in young adults and adolescents. The treatment of Ewing
sarcoma depends on multiple approaches, including risk-adapted,
intensive, adjuvant and neo-adjuvant chemotherapies with radiotherapy
and/or surgery for control of the possible metastatic and primary
sites of the disease. The optimization of Ewing sarcoma multiple
modalities of therapeutic strategies has rose from efforts of
numerous national and international groups in North America and
Europe to form cooperation between medical oncologists and
pediatrics. Ewing sarcoma is the second most frequently diagnosed
form of primary bone cancer in children and young adults. The disease
can occur in any individual at any age, but it is uncommon in people
aged over 30 years. It develops most commonly in individuals aged
between 10 and 20 years, who are witnessing rapid growth of bones.
Increasing incidence of Ewing sarcoma worldwide and initiatives taken
by government organizations to reduce the rate of morbidity caused by
Ewing sarcoma are factors driving the Ewing sarcoma treatment market.
Currently, no approved treatments are available for Ewing sarcoma.
This has led to increase in research and development activities to
launch an approved treatment for Ewing sarcoma by leading players.
The global market for Ewing sarcoma treatment can be segmented based
on type, diagnostic test, treatment, end-user, and geography. Based
on type, the market has been categorized into extra osseous Ewing
sarcoma, Askin tumor, and primitive neuroectodermal tumor. Extra
osseous Ewing sarcoma is related with tumor in soft tissue, while
Askin tumor is related with Ewing sarcoma that appears in the chest
wall. Primitive neuroectodermal tumor is related with Ewing sarcoma
wherein cells looks like nerve cells. Based on diagnostic test, the
Ewing sarcoma treatment market has been segmented into CT scan, MRI
scan, biopsy of the bone marrow, and blood tests. Based on treatment,
the market has been divided into chemotherapy, surgery, and
radiotherapy. Based on end-user, the Ewing sarcoma treatment market
has been classified into hospitals, cancer treating centers, and
specialty clinics.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37700
Based on geography, the global Ewing sarcoma treatment market can be
segmented into five major regions: North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa. Furthermore,
the North America Ewing Sarcoma treatment market has been
sub-segmented into U.S. and Canada. The Ewing sarcoma treatment
market in Europe has been sub-divided into Germany, U.K., France,
Spain, Italy, and Rest of Europe. The Ewing sarcoma treatment market
in Asia Pacific has been sub-segmented into China, Japan, India,
Australia & New Zealand, and Rest of Asia Pacific. The Latin
America Ewing sarcoma treatment market has been sub-divided into
Brazil, Mexico, and Rest of Latin America. The Ewing sarcoma
treatment market in Middle East & Africa has been sub-segmented
into GCC, South Africa, Israel, and Rest of Middle East & Africa.
North America dominates the global Ewing sarcoma treatment market,
followed by Europe. Key factors driving the market in these two
regions are growing awareness about Ewing Sarcoma amongst adults and
availability of sophisticated and technologically advanced treatment
options in these regions. The rate of incidence of Ewing sarcoma is
lower in Asia and Africa.
Some of the top players operating in the global Ewing sarcoma
treatment market are Gradalis, Pfizer Inc., Daiichi Sankyo Company,
Limited, Genzyme Corporation, NantPharma, F. Hoffmann-La Roche Ltd,
Celgene Corporation, Eli Lilly and Company, Bayer AG, Novartis AG,
Ignyta, and Esai Co., Ltd.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=37700<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment